News

Novel Phenomics NASH In Vitro Assay Presented by InSphero AG and PharmaNest Inc at 2021 Society of Toxicology Meeting Introduction of key technology to accelerate

InSphero CEO and co-founder, Jan Lichtenberg, brings extensive experience as an entrepreneur and a technical disruptor at the intersection of 3D in vitro technologies and automation.

New partnership will focus on establishing and advancing high content screening solutions using complex, physiologically relevant 3D cell-based disease models.

New SAB members bring rich experience and expertise in human disease modeling and translational toxicology as well as a keen interest in 3D in vitro technologies.

Long-term collaborative research partnership continues to serve as successful biotechnology incubator for disruptive drug discovery and safety testing platforms and applications.

Unique packaging solution, engineered to protect delicate assay-ready 3D cell-based tissue models during express shipping, captivates judges in internationally recognized competition

Ingenious InFloat™ Shipping System protects and secures delicate microtissues in transit, ensuring they are ready to use in drug discovery and safety testing experiments upon arrival.

New program will enable academic research teams to develop applications for plug-and-play organ-on-chip technology without requiring resource intensive platform and model development

Online purchasing option for assay-ready 3D InSight™ Human Liver Microtissues to help eliminate 3D model development delays for labs ready to resume compound testing and risk assessment.

Move optimally positions InSphero to build on its business development, scientific research, and operational teams.

New study confirms hanging drop microfluidics platform for miniaturized islet perifusion assays enables high-resolution assessment of islet insulin secretion from single human islets over time.